The NF-κB p65/miR-23a-27a-24 cluster is a target for leukemia treatment

Yong-Chang Zhang; Hui Ye; Zhi Zeng; Y. Eugene Chin; Yu-Ning Huang; Guo-Hui Fu

doi:10.18632/oncotarget.5591

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The NF-κB p65/miR-23a-27a-24 cluster is a target for leukemia treatment

Yong-Chang Zhang, Hui Ye, Zhi Zeng, Y. Eugene Chin, Yu-Ning Huang and Guo-Hui Fu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:33554-33567. https://doi.org/10.18632/oncotarget.5591

Metrics: PDF 4381 views | HTML 2101 views | ?

Abstract

Yong-Chang Zhang1,*, Hui Ye1,*, Zhi Zeng1,*, Y. Eugene Chin2, Yu-Ning Huang1 and Guo-Hui Fu1

1 Pathology Center, Shanghai General Hospital/Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2 Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) and Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China

* These authors have contributed equally to the first author

Correspondence to:

Guo-Hui Fu, email:

Keywords: NF-κB p65, miR-23a-27a-24 cluster, erythroid differentiation, leukemia

Received: March 12, 2015 Accepted: August 23, 2015 Published: September 10, 2015

Abstract

p65 is a transcription factor that is involved in many physiological and pathologic processes. Here we report that p65 strongly binds to the miR-23a-27a-24 cluster promoter to up-regulate its expression. As bone marrow-derived cells differentiate into red blood cells in vitro, p65/miR-23a-27a-24 cluster expression increases sharply and then declines before the appearance of red blood cells, suggesting that this cluster is negatively related to erythroid terminal differentiation. Bioinformatic and molecular biology experiments confirmed that the miR-23a-27a-24 cluster inhibited the expression of the erythroid proteome and contributed to erythroleukemia progression. In addition, high level of the p65/miR-23a-27a-24 cluster was found in APL and AML cell lines and in nucleated peripheral blood cells from leukemia patients. Furthermore, anti-leukemia drugs significantly inhibited the expression of the p65/miR-23a-27a-24 cluster in leukemia cells. Administration of the p65 inhibitor parthenolide significantly improved hematology and myelogram indices while prolonging the life span of erythroleukemia mice. Meanwhile, stable overexpression of these three miRNAs in mouse erythroleukemia cells enhanced cell malignancy. Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5591

Publication Alerts

Research Papers:

The NF-κB p65/miR-23a-27a-24 cluster is a target for leukemia treatment

Abstract